FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809672010> ?p ?o ?g. }

• W2809672010 abstract "The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monotherapy in reducing disease activity and signs and symptoms of RA, as well as in improving physical function, with similar rates of adverse and serious adverse events. We report the effects of sarilumab versus adalimumab on patient-reported outcomes (PROs). Patients with active RA intolerant of, or inadequate responders to, methotrexate were randomized to sarilumab 200 mg plus placebo every 2 weeks (q2w; n = 184) or adalimumab 40 mg plus placebo q2w (n = 185). Dose escalation to weekly administration of adalimumab or matching placebo was permitted at week 16. PROs assessed at baseline and weeks 12 and 24 included patient global assessment of disease activity (PtGA), pain and morning stiffness visual analogue scales (VASs), Health Assessment Questionnaire Disability Index (HAQ-DI), 36-item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Rheumatoid Arthritis Impact of Disease (RAID), and rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Between-group differences in least-squares mean (LSM) changes from baseline were analyzed. p < 0.05 was considered significant for PROs in a predefined hierarchy. For PROs not in the hierarchy, nominal p values are provided. Proportions of patients reporting improvements greater than or equal to the minimal clinically important difference (MCID) and achieving normative values were assessed. At week 24, sarilumab treatment resulted in significantly greater LSM changes from baseline than adalimumab monotherapy in HAQ-DI (p < 0.005), PtGA (p < 0.001), pain VAS (p < 0.001), and SF-36 Physical Component Summary (PCS) (p < 0.001). Greater LSM changes were reported for sarilumab than for adalimumab in RAID (nominal p < 0.001), morning stiffness VAS (nominal p < 0.05), and WPS-RA (nominal p < 0.005). Between-group differences in FACIT-F and SF-36 Mental Component Summary (MCS) were not significant. More patients reported improvements greater than or equal to the MCID in HAQ-DI (nominal p < 0.01), RAID (nominal p < 0.01), SF-36 PCS (nominal p < 0.005), and morning stiffness (nominal p < 0.05), as well as greater than or equal to the normative values in HAQ-DI (p < 0.05), with sarilumab versus adalimumab. In parallel with the clinical efficacy profile previously reported, sarilumab monotherapy resulted in greater improvements across multiple PROs than adalimumab monotherapy. ClinicalTrials.gov, NCT02332590 . Registered on 5 January 2015." @default.
• W2809672010 created "2018-06-29" @default.
• W2809672010 creator A5004560391 @default.
• W2809672010 creator A5005424988 @default.
• W2809672010 creator A5009151561 @default.
• W2809672010 creator A5012283576 @default.
• W2809672010 creator A5016395117 @default.
• W2809672010 creator A5029781530 @default.
• W2809672010 creator A5033861263 @default.
• W2809672010 creator A5042476895 @default.
• W2809672010 creator A5064777057 @default.
• W2809672010 creator A5069919512 @default.
• W2809672010 creator A5076851275 @default.
• W2809672010 creator A5091895459 @default.
• W2809672010 date "2018-06-19" @default.
• W2809672010 modified "2023-10-06" @default.
• W2809672010 title "Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis" @default.
• W2809672010 cites W1492940207 @default.
• W2809672010 cites W1494568019 @default.
• W2809672010 cites W1586828706 @default.
• W2809672010 cites W1968354608 @default.
• W2809672010 cites W1976591039 @default.
• W2809672010 cites W2002139673 @default.
• W2809672010 cites W2004270254 @default.
• W2809672010 cites W2010363255 @default.
• W2809672010 cites W2015522069 @default.
• W2809672010 cites W2019798588 @default.
• W2809672010 cites W2020888702 @default.
• W2809672010 cites W2025456283 @default.
• W2809672010 cites W2033299724 @default.
• W2809672010 cites W2040963445 @default.
• W2809672010 cites W2054059257 @default.
• W2809672010 cites W2069826111 @default.
• W2809672010 cites W2102207725 @default.
• W2809672010 cites W2104389209 @default.
• W2809672010 cites W2110598751 @default.
• W2809672010 cites W2112234440 @default.
• W2809672010 cites W2118771994 @default.
• W2809672010 cites W2123408911 @default.
• W2809672010 cites W2133103918 @default.
• W2809672010 cites W2134114605 @default.
• W2809672010 cites W2137884440 @default.
• W2809672010 cites W2139323151 @default.
• W2809672010 cites W2139629261 @default.
• W2809672010 cites W2149564130 @default.
• W2809672010 cites W2150819298 @default.
• W2809672010 cites W2156271885 @default.
• W2809672010 cites W2159659438 @default.
• W2809672010 cites W2159705610 @default.
• W2809672010 cites W2161344815 @default.
• W2809672010 cites W2161461174 @default.
• W2809672010 cites W2163203964 @default.
• W2809672010 cites W2205328596 @default.
• W2809672010 cites W2415111211 @default.
• W2809672010 cites W2513662764 @default.
• W2809672010 cites W2557016092 @default.
• W2809672010 cites W2593835974 @default.
• W2809672010 cites W4250968058 @default.
• W2809672010 doi "https://doi.org/10.1186/s13075-018-1614-z" @default.
• W2809672010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6009058" @default.
• W2809672010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29921318" @default.
• W2809672010 hasPublicationYear "2018" @default.
• W2809672010 type Work @default.
• W2809672010 sameAs 2809672010 @default.
• W2809672010 citedByCount "27" @default.
• W2809672010 countsByYear W28096720102019 @default.
• W2809672010 countsByYear W28096720102020 @default.
• W2809672010 countsByYear W28096720102021 @default.
• W2809672010 countsByYear W28096720102022 @default.
• W2809672010 countsByYear W28096720102023 @default.
• W2809672010 crossrefType "journal-article" @default.
• W2809672010 hasAuthorship W2809672010A5004560391 @default.
• W2809672010 hasAuthorship W2809672010A5005424988 @default.
• W2809672010 hasAuthorship W2809672010A5009151561 @default.
• W2809672010 hasAuthorship W2809672010A5012283576 @default.
• W2809672010 hasAuthorship W2809672010A5016395117 @default.
• W2809672010 hasAuthorship W2809672010A5029781530 @default.
• W2809672010 hasAuthorship W2809672010A5033861263 @default.
• W2809672010 hasAuthorship W2809672010A5042476895 @default.
• W2809672010 hasAuthorship W2809672010A5064777057 @default.
• W2809672010 hasAuthorship W2809672010A5069919512 @default.
• W2809672010 hasAuthorship W2809672010A5076851275 @default.
• W2809672010 hasAuthorship W2809672010A5091895459 @default.
• W2809672010 hasBestOaLocation W28096720101 @default.
• W2809672010 hasConcept C111278954 @default.
• W2809672010 hasConcept C126322002 @default.
• W2809672010 hasConcept C142724271 @default.
• W2809672010 hasConcept C168563851 @default.
• W2809672010 hasConcept C1862650 @default.
• W2809672010 hasConcept C197934379 @default.
• W2809672010 hasConcept C204787440 @default.
• W2809672010 hasConcept C27081682 @default.
• W2809672010 hasConcept C2777575956 @default.
• W2809672010 hasConcept C2778715236 @default.
• W2809672010 hasConcept C2780132546 @default.
• W2809672010 hasConcept C71924100 @default.
• W2809672010 hasConceptScore W2809672010C111278954 @default.
• W2809672010 hasConceptScore W2809672010C126322002 @default.
• W2809672010 hasConceptScore W2809672010C142724271 @default.
• W2809672010 hasConceptScore W2809672010C168563851 @default.

• next